Monitor the closing of the offering to see actual proceeds raised; without a minimum, the company may only raise a fraction of the $22.7M, accelerating the need for further dilutive financing. Track the Phase 2b ADDRESS-LC long COVID data expected in late summer 2026 as a potential catalyst, but this Phase 2b Parkinson's data, while positive, is preliminary and from a small trial. Given the serial dilution pattern (19 filings in 24 months) and ongoing cash burn with no revenue, near-term price pressure from this offering is likely.
Executive Summary
BioVie Inc. filed Amendment No. 3 to its S-1 registration statement for a best-efforts offering of up to 16,025,641 shares of Class A common stock, pre-funded warrants, and common warrants at an assumed combined price of $1.56 per unit. The company, a clinical-stage biopharma with no approved products or revenue, estimates net proceeds of ~$22.7M for working capital but the offering has no minimum, so it may raise significantly less. The filing highlights substantial doubt about going concern, an accumulated deficit of ~$374.3M, and ongoing litigation risks, making this a dilutive capital raise for a pre-revenue company with positive but early-stage Phase 2b Parkinson's data.
Key Financial Metrics
Key Facts
- Best-efforts offering of up to 16,025,641 shares of Class A common stock, plus an equal number of pre-funded warrants and common warrants to purchase additional shares.
- Assumed combined public offering price of $1.56 per share and accompanying common warrant, with common warrants exercisable at $1.95 (125% of offering price) for 5 years.
- No minimum offering amount required, meaning the company may raise far less than the maximum estimated $22.7 million in net proceeds.
- As of June 30, 2026, the company had $9.0M in cash and cash equivalents, an accumulated deficit of $374.3M, and total stockholders' equity of $10.3M.
- Substantial doubt about the company's ability to continue as a going concern is explicitly noted in the filing and the auditor's report.
- Clinical-stage biopharma developing bezisterim for neurodegenerative disorders (Parkinson's, Alzheimer's, long COVID) and BIV201 for liver cirrhosis; no approved products or revenue.
- Phase 2b SUNRISE-PD trial for early Parkinson's showed statistically significant reduction in composite neuroinflammation measure (nominal p=0.0018) but was small (57 patients) and exploratory in nature.
- The offering is dilutive: new investors will experience immediate dilution of $0.17 per share based on as-adjusted net tangible book value.
- Existing warrants and stock options could add up to 10.1M additional shares of dilution.
- Nasdaq delisting risk exists if the offering is not deemed a 'public offering' under Nasdaq's stockholder approval rule.
- The company has 19 offering/registration filings in the last 24 months, indicating significant capital needs.
Financial Impact
Maximum estimated net proceeds of ~$22.7M from the offering, but no minimum means actual could be substantially lower. The company had $9.0M in cash at June 30, 2026, and a $374.3M accumulated deficit.
Risk Factors
- Substantial doubt about going concern with $374M accumulated deficit and no product revenue.
- Dilution: offering alone adds up to 16M+ shares, plus 10.1M shares from existing warrants/options, versus 8.5M current shares outstanding.
- NASDAQ delisting risk if offering is not deemed a public offering per Nasdaq rules.
- Execution risk: Phase 2b Parkinson's data positive but small (57 patients); Phase 3 regulatory path uncertain.
- No minimum offering amount means the company may raise far less than needed, requiring additional dilutive capital.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 2 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-1/A Filing (Primary) | 0001520138-26-000350 |
| Document: bivi_s1a3ex1z1.htm | 0001520138-26-000350 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 7d ago | Press Release | $1.37 | awaiting T+20 | — | $1.32 (−3.65%) |
Sep 15, 2026 5w ago | Press Release | $1.75 $1.20 | ▼ −31.43% | ▼ −34.41% | $1.32 (−24.57%) |
Aug 14, 2026 10w ago | S-1/A | $1.17 $1.75 | ▼ −49.57% | ▼ −51.55% | $1.32 (−12.82%) |
Aug 6, 2026 11w ago | S-1/A | $1.35 $2.03 | ▼ −50.37% | ▼ −49.77% | $1.32 (+2.22%) |
Aug 6, 2026 11w ago | 8-K | $1.35 $2.03 | ▲ +50.37% | ▲ +49.77% | $1.32 (−2.22%) |
Jul 31, 2026 12w ago | S-1/A | $1.62 $2.28 | ▼ −40.74% | ▼ −39.50% | $1.32 (+18.52%) |
Jun 30, 2026 16w ago | EFFECT | $1.94 $1.37 | ▲ +29.38% | ▲ +28.35% | $1.32 (+31.96%) |
Apr 27, 2026 26w ago | Press Release | $1.59 $1.44 | ▼ −9.43% | ▼ −14.39% | $1.32 (−16.98%) |
Apr 14, 2026 27w ago | Press Release | $1.46 $1.35 | ▼ −7.53% | ▼ −13.83% | $1.32 (−9.59%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers